These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 36326181)

  • 21. Peptide-based drug discovery: Current status and recent advances.
    Sharma K; Sharma KK; Sharma A; Jain R
    Drug Discov Today; 2023 Feb; 28(2):103464. PubMed ID: 36481586
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Hashemi ZS; Zarei M; Fath MK; Ganji M; Farahani MS; Afsharnouri F; Pourzardosht N; Khalesi B; Jahangiri A; Rahbar MR; Khalili S
    Front Mol Biosci; 2021; 8():669431. PubMed ID: 33996914
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent developments in engineering protein-protein interactions using phage display.
    Liang CT; Roscow OMA; Zhang W
    Protein Eng Des Sel; 2021 Feb; 34():. PubMed ID: 34117768
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Target identification of natural and traditional medicines with quantitative chemical proteomics approaches.
    Wang J; Gao L; Lee YM; Kalesh KA; Ong YS; Lim J; Jee JE; Sun H; Lee SS; Hua ZC; Lin Q
    Pharmacol Ther; 2016 Jun; 162():10-22. PubMed ID: 26808165
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Venom peptides as therapeutics: advances, challenges and the future of venom-peptide discovery.
    Robinson SD; Undheim EAB; Ueberheide B; King GF
    Expert Rev Proteomics; 2017 Oct; 14(10):931-939. PubMed ID: 28879805
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting intracellular protein-protein interactions with cell-permeable cyclic peptides.
    Qian Z; Dougherty PG; Pei D
    Curr Opin Chem Biol; 2017 Jun; 38():80-86. PubMed ID: 28388463
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increasing the range of drug targets: interacting peptides provide leads for the development of oncoprotein inhibitors.
    Groner B; Weber A; Mack L
    Bioengineered; 2012; 3(6):320-5. PubMed ID: 22825353
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peptide Agonists and Antagonists with Potential Application in Neurological Disorders.
    Russo A; La Manna S; Morelli G; Novellino E; Marasco D
    Recent Pat CNS Drug Discov; 2016; 10(2):76-89. PubMed ID: 27108811
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In situ click chemistry: from small molecule discovery to synthetic antibodies.
    Millward SW; Agnew HD; Lai B; Lee SS; Lim J; Nag A; Pitram S; Rohde R; Heath JR
    Integr Biol (Camb); 2013 Jan; 5(1):87-95. PubMed ID: 22836343
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting protein-protein interactions in hematologic malignancies: still a challenge or a great opportunity for future therapies?
    Cierpicki T; Grembecka J
    Immunol Rev; 2015 Jan; 263(1):279-301. PubMed ID: 25510283
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Computational tools for exploring peptide-membrane interactions in gram-positive bacteria.
    Kumar S; Balaya RDA; Kanekar S; Raju R; Prasad TSK; Kandasamy RK
    Comput Struct Biotechnol J; 2023; 21():1995-2008. PubMed ID: 36950221
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emerging roles of allosteric modulators in the regulation of protein-protein interactions (PPIs): A new paradigm for PPI drug discovery.
    Ni D; Lu S; Zhang J
    Med Res Rev; 2019 Nov; 39(6):2314-2342. PubMed ID: 30957264
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ligand-based peptide design and combinatorial peptide libraries to target G protein-coupled receptors.
    Gruber CW; Muttenthaler M; Freissmuth M
    Curr Pharm Des; 2010; 16(28):3071-88. PubMed ID: 20687879
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibitors of protein-protein interactions (PPIs): an analysis of scaffold choices and buried surface area.
    Ran X; Gestwicki JE
    Curr Opin Chem Biol; 2018 Jun; 44():75-86. PubMed ID: 29908451
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design and structure of peptide and peptidomimetic antagonists of protein-protein interaction.
    Sillerud LO; Larson RS
    Curr Protein Pept Sci; 2005 Apr; 6(2):151-69. PubMed ID: 15853652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peptide therapeutics: targeting the undruggable space.
    Tsomaia N
    Eur J Med Chem; 2015 Apr; 94():459-70. PubMed ID: 25591543
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In silico structure-based approaches to discover protein-protein interaction-targeting drugs.
    Shin WH; Christoffer CW; Kihara D
    Methods; 2017 Dec; 131():22-32. PubMed ID: 28802714
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.